Alchemab Therapeutics awarded £1.7m from Innovate UK to develop Huntington’s disease therapy towards human trials


Alchemab Therapeutics has been awarded a £1.7million grant from Innovate UK to accelerate its development of a first-in-class therapy for Huntington’s disease.

The Babraham Research Campus-based biotechnology company is working with the Medicines Discovery Catapult (MDC) on preclinical studies of its panel of antibodies as it takes them towards human studies.

Read the full article here